Achilles Therapeutics plc – NASDAQ:ACHL
Achilles Therapeutics stock price today
$1.48
+0.35
+30.97%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Achilles Therapeutics stock price monthly change
+30.94%
month
Achilles Therapeutics stock price quarterly change
+30.94%
quarter
Achilles Therapeutics stock price yearly change
+30.88%
year
Achilles Therapeutics key metrics
Market Cap | 40.44M |
Enterprise value | N/A |
P/E | -0.52 |
EV/Sales | N/A |
EV/EBITDA | 1.85 |
Price/Sales | N/A |
Price/Book | 0.18 |
PEG ratio | -0.01 |
EPS | -1.60 |
Revenue | N/A |
EBITDA | -68.82M |
Income | -64.58M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAchilles Therapeutics stock price history
Achilles Therapeutics stock forecast
Achilles Therapeutics financial statements
| Jun 2023 | 0 | -16.84M | |
|---|---|---|---|
| Sep 2023 | 0 | -16.68M | |
| Dec 2023 | 0 | -18.79M | |
| Mar 2024 | 0 | -12.26M |
| Dec 2023 | 0 | -18.79M | |
|---|---|---|---|
| Mar 2024 | 0 | -12.26M | |
| Sep 2025 | 0 | -20.94M | |
| Dec 2025 | 0 | -20.94M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 197907000 | 24.06M | 12.16% |
|---|---|---|---|
| Sep 2023 | 175338000 | 21.85M | 12.46% |
| Dec 2023 | 161456000 | 19.08M | 11.82% |
| Mar 2024 | 145741000 | 15.39M | 10.56% |
| Jun 2023 | -17.40K | -537 | 0 |
|---|---|---|---|
| Sep 2023 | 1.07M | -61.38K | 8.03K |
| Dec 2023 | -14.22M | -45.60K | -4 |
| Mar 2024 | -17.49M | -694.60K | 4.99K |
Achilles Therapeutics alternative data
| Aug 2023 | 234 |
|---|---|
| Sep 2023 | 234 |
| Oct 2023 | 234 |
| Nov 2023 | 234 |
| Dec 2023 | 234 |
| Jan 2024 | 234 |
| Feb 2024 | 234 |
| Mar 2024 | 234 |
| Apr 2024 | 234 |
| May 2024 | 204 |
| Jun 2024 | 204 |
| Jul 2024 | 204 |
Achilles Therapeutics other data
35.33%
-40.28%
of ACHL is owned by hedge funds
13.82M
-7.83M
shares is hold by hedge funds
-
What's the price of Achilles Therapeutics stock today?
One share of Achilles Therapeutics stock can currently be purchased for approximately $1.48.
-
When is Achilles Therapeutics's next earnings date?
Unfortunately, Achilles Therapeutics's (ACHL) next earnings date is currently unknown.
-
Does Achilles Therapeutics pay dividends?
No, Achilles Therapeutics does not pay dividends.
-
How much money does Achilles Therapeutics make?
Achilles Therapeutics has a market capitalization of 40.44M.
-
What is Achilles Therapeutics's stock symbol?
Achilles Therapeutics plc is traded on the NASDAQ under the ticker symbol "ACHL".
-
What is Achilles Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Achilles Therapeutics?
Shares of Achilles Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Achilles Therapeutics have?
As Jul 2024, Achilles Therapeutics employs 204 workers, which is 13% less then previous quarter.
-
When Achilles Therapeutics went public?
Achilles Therapeutics plc is publicly traded company for more then 4 years since IPO on 31 Mar 2021.
-
What is Achilles Therapeutics's official website?
The official website for Achilles Therapeutics is achillestx.com.
-
How can i contact Achilles Therapeutics?
Achilles Therapeutics can be reached via phone at +44 20 8154 4600.
Achilles Therapeutics company profile:
Achilles Therapeutics plc
achillestx.comExchange:
NASDAQ
Full time employees:
204
Industry:
Biotechnology
Sector:
Healthcare
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
245 Hammersmith Road
London, W6 8PW
London, W6 8PW
CIK: 0001830749
ISIN: US00449L1026
CUSIP: 00449L102
